Press Releases

    • July 7, 2020

    Nemaura Medical Submits PMA Application for sugarBEAT® to U.S. FDA

    Company to Participate in RedChip Webinar on Tuesday, July 7, at 11 a.m. ET to Discuss Commercialization Progress Loughborough,...

    Read more
    June 30, 2020

    Nemaura Medical Reports Results and Provides Business Update for the Fiscal Year Ended March 31, 2020

    Loughborough, England, June 30, 2020 – Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a...

    Read more
    June 26, 2020

    Nemaura Medical Interview to Air on Bloomberg International on the RedChip Money Report

    Loughborough, England, June 26, 2020 – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company...

    Read more
    June 24, 2020

    Nemaura Medical CEO to Participate in Investor Webinar and Q&A Session on July 7, 2020

    Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic...

    Read more
    June 16, 2020

    Nemaura Participated as Guest Speaker at DiabetesMine™ D-Data ExChange 2020

    LOUGHBOROUGH, England–(BUSINESS WIRE)–Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based...

    Read more
    June 10, 2020

    Nemaura Medical to Present at Credit Suisse 2020 Virtual Diabetes Sessions

    Loughborough, England, June 9, 2020 — Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company...

    Read more
    June 9, 2020

    Nemaura Medical Set to Join the Russell 2000® Index and Russell 3000® Index

    Loughborough, England, June 9, 2020 — Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company...

    Read more
    May 19, 2020

    Nemaura Medical 2020 Stock Incentive Plan Approved at Annual General Meeting

    Loughborough, England, May 19, 2020 — Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company...

    Read more
    May 11, 2020

    Nemaura reports positive data from early head-to-head comparison with a major incumbent CGM Device

    sugarBEAT® was developed as a viable, flexible, and cost-effective alternative to invasive continuous glucose monitors (“CGM”), and the company...

    Read more
    May 5, 2020

    Nemaura Medical Announces Interview with CEO to Air on May 11

    Loughborough, England, May 5, 2020 — Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company...

    Read more